Microarray coupled with methyl-CpG targeted transcriptional activation (MeTA-array) identifies hypermethylated genes containing the stringent criteria of CpG islands at high frequency

Epigenetics

Volumn 6, Issue 6, 2011, Pages 752-759

  Sato, Yuko ^a   Horii, Akira ^a   Fukushige, Shinichi ^a,b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CpG island; DNA demethylating agent; DNA methylation; MBD; MeTA; Microarray

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE DEACETYLASE; METHYL CPG BINDING PROTEIN 2; TRICHOSTATIN A;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; EMBRYO; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL CULTURE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; UPREGULATION;

EID: 79958733589     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.6.15906     Document Type: Article

References (42)

1. Bird AP, Wolffe AP. Methylation-induced repressionbelts, braces and chromatin. Cell 1999; 99:451-454.
2. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 2006; 103:1412-1417.
3. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39:457-466.
4. Maher ER, Reik W. Beckwith-Wiedemann syndrome: Imprinting in clusters revisited. J Clin Invest 2000; 105:247-252.
5. Nicholls RD, Saitoh S, Horsthemke B. Imprinting in Prader-Willi and Angelman syndromes. Trens Genet 1998; 14:194-200.
6. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8:355-367.
7. Herman JG, Baylin SB. Gene soilencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-2054.
8. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321:209-213.
9. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196:261-282.
10. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002; 99:3740-3745.
11. Illingworth RS, Bird AP. CpG islands-'A rough guide'. FEBS Lett 2009; 583:1713-1720.
12. Watt F, Molloy PL. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Gev 1988; 2:1136-1143.
13. Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 1991; 64:1123-1134.
14. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 1998; 18:6538-47.
15. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393:386-389.
16. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 1999; 23:58-61.
17. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 1999; 23:62-66.
18. Sarraf SA, Stancheva I. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol Cell 2004; 15:595-605.
19. Kondo E, Gu Z, Horii A, Fukushige S. The thymine DNA glycosylase MBD4 represses transcription and is associated with methylated p16INK4a and hMLH1 genes. Mol Cell Biol 2005; 25:4388-4396.
20. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409:207-211.
21. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 32:141-149.
22. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, et al. Chromosome-wide and promoterspecific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005; 37:853-862.
23. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new corepressor, DMAP1, to form a complex at replication foci. Nat Genet 2000; 25:269-277.
24. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000; 24:88-91.
25. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000; 25: 338-342.
26. Bachman KE, Rountree MR, Baylin SB. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem 2001; 276:32282-32287.
27. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 2001; 20:2536-2544.
28. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 2003; 22:6335-6345.
29. Cross SH, Chariton JA, Nan X, Bird AP. Purification of CpG islands using a methylated DNA binding column.Nat Genet 1994; 6:236-244.
30. Schumacher A, Kapranov P, Kaminsky Z, Flanagan J, Assadzadeh A, Yau P, et al. Microarray-based DNA methylation profiling: Technology and applications. Nucleic Acids Res 2006; 34:528-542.
31. Suzuki MM, Bird A. DNA methylation landscape: provocate insights from epigenomics. Nat Rev Genet 2008; 9:465-476.
32. Fukushige S, Kondo E, Horii A. Methyl-CpG targeted transcriptional activation allows re-expression of tumor suppressor genes in human cancer cells. Biochem Biophys Res Commun 2008; 377:600-605.
33. Fukushige S, Kondo E, Horii A. Methyl-CpG targeted recruitment of p300 reactivates tumor suppressor genes in human cancer cells. Biochem Biophys Res Commun 2009; 379:1021-1026.
34. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006; 38:1378-1385.
35. Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F, et al. Purification, sequence and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992; 69:905-914.
36. Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res 2003; 31:1765-1774.
37. Lopez-Serra L, Ballestar E, Ropero S, Setien F, Billard L-M, Fraga MF, et al. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene 2008; 27:3556-3566.
38. Clouaire T, de Las Heras JI, Merusi C, Stancheva I. Recruitment of MBD1 to target genes requires sequence-specific interaction of the MBD domain with methylated DNA. Nucleic Acids Res 2010; 38: 4620-4634.
39. Kondo E, Horii A, Fukushige S. The human PMS2L proteins do not interact with hMLH1, a major DNA mismatch repair protein. J Biochem 1999; 125:818-825.
40. Mori Y, Shiwaku H, Fukushige S, Wakatsuki S, Sato M, Nukiwa T, et al. Alternative splicing of hMSH2 in normal human tissues. Hum Genet 1997; 99:590-595.
41. Ogawa K, Shiga K, Saijo S, Ogawa T, Kimura N, Horii A. A novel G106D alteration of the SDHD gene in a pedigree with familial paraganglioma. Am J Med Genet 2006; 140:2441-2446.
42. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is a major downstream target of MAPK1/ERK2 in pancreatic cancer. Oncogene 2006; 25:4831-4839.